Article
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Head & neck - 1 Nov 2014
Hah J Hun, Zhao Mei, Pickering Curtis R, Frederick Mitchell J, Andrews Genevieve A, Jasser Samar A, Fooshee David R, Milas Zvonimir L, Galer Chad, Sano Daisuke, William William N, Kim Edward, Heymach John, Byers Lauren A, Papadimitrakopoulou Vali, Myers Jeffrey N
Abstract excerpt
BACKGROUND: The purpose of this study was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. METHODS: Erlotinib sensitivity was determined by methyl thiazolyl-tetrazolium (MTT) assays....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.